ABSTRACT Background The NHS Cancer Drugs Fund (CDF) was established in 2010 to
reduce delays and improve access to cancer drugs, including those that had been …

PURPOSE To provide recommendations for the management of patients with metastatic
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …

Appropriate safety evaluations of anticancer drugs are crucial to assess their benefit–risk
ratio. Substantial evidence shows that clinicians under-report harm in clinical trials, and at …

Background: Multi-targeted vascular endothelial growth factor receptor (VEGFR) tyrosine
kinase inhibitors (TKIs) are known to cause cardiac toxicity, but the relative risk (RR) of QTc …

Background Systemic therapy (ST) can be deferred in patients who have metastatic renal
cell carcinoma (mRCC) and slow‐growing metastases. Currently, this subset of patients …

Excitement about the dramatic increase in potential successful anticancer medicines in
recent years is hampered by the high costs involved as well as the length of time traditional …

Background Recent randomised phase III trials have led to the approval of several immune
checkpoint inhibitors for unresectable or metastatic melanoma (MM). These trials all …

Background The treatment landscape of metastatic clear cell renal cell carcinoma (mccRCC)
has been transformed by targeted therapies with tyrosine kinase inhibitors (TKI) and more …

Background Nivolumab plus ipilimumab (NIVO+ IPI) has demonstrated long‐term efficacy
and safety in patients with previously untreated, advanced renal cell carcinoma (aRCC) …

The most common type of cancer originating in the kidney is renal cell carcinoma (RCC). In
both localized and advanced RCC, a number of clinical, pathologic, and molecular factors …